Described are stable topical formulations useful in the treatment of viral wart infection, demodex infection and bacterial infection of the skin, and genitalia and the method of treating viral wart infection, demodex infection and bacterial infection of the skin, and genitalia with said compositions.

Described are stable topical formulations useful in the treatment of viral wart infection, demodex infection and bacterial infection of the skin, and genitalia and the method of treating viral wart infection, demodex infection and bacterial infection of the skin, and genitalia with said compositions.

The present invention is directed to PVP-I formulations having enhanced virucidal activity. The formulations are intended for topical administration for treatment and/or decreased risk of microbial infections in subjects. The formulations include PVP-I and other ingredients selected to enhance the virucidal activity of the formulation over PVP-I alone.

The present invention is directed to PVP-I formulations having enhanced virucidal activity. The formulations are intended for topical administration for treatment and/or decreased risk of microbial infections in subjects. The formulations include PVP-I and other ingredients selected to enhance the virucidal activity of the formulation over PVP-I alone.

The present invention is directed to PVP-I formulations having enhanced virucidal activity. The formulations are intended for topical administration for treatment and/or decreased risk of microbial infections in subjects. The formulations include PVP-I and other ingredients selected to enhance the virucidal activity of the formulation over PVP-I alone.

Oral formulations include anti-viral agents. These oral formulations are manufactured in various permutations such as a chewing gum or lozenge which incorporate anti-viral agents for protecting an individuals body from viruses.

Oral formulations include anti-viral agents. These oral formulations are manufactured in various permutations such as a chewing gum or lozenge which incorporate anti-viral agents for protecting an individuals body from viruses.

A composition having molecular iodine in combination with a polyol can be used for control and treatment of microbes and infections on biological and non-biological surfaces. Compositions have a combination of molecular iodine (I2) and an acceptable source of iodate (IO3), and a buffering acid (inorganic or organic), in combination with a polyol in an amount of 3-50% by weight. The present compositions can also have prebiotic and probiotic properties on biological surfaces and membranes for the control and treatment of infection as well as the support of growth of commensal microbes and the control of pathogenic microbes.

A composition having molecular iodine in combination with a polyol can be used for control and treatment of microbes and infections on biological and non-biological surfaces. Compositions have a combination of molecular iodine (I2) and an acceptable source of iodate (IO3), and a buffering acid (inorganic or organic), in combination with a polyol in an amount of 3-50% by weight. The present compositions can also have prebiotic and probiotic properties on biological surfaces and membranes for the control and treatment of infection as well as the support of growth of commensal microbes and the control of pathogenic microbes.

The present patent application relates a process for the production of compressed tablets using specific coated particles, wherein the coating (system) comprises at least one wax and/or at least one fat. Furthermore it relates to compressed (compacted) tablets and as well as to specific coated particles.